J&J Plots Five-Year Pharma Growth Plan Around Mega-Brands And Launches

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Management outlined how the company plans to achieve above-market compound-annual growth from 2016 to 2021 during an R&D Day near its New Jersey headquarters.

female hand arranging wood block stacking as step stair. Business concept growth success process
J&J is building blockbusters to drive growth

Johnson & Johnson's strategy to outpace its branded pharmaceutical peers by achieving above-market compound annual growth over the five-year period from 2016 to 2021 will require building several blockbuster brands into "mega-blockbusters" and launching new commercial successes, Worldwide Chairman-Pharmaceuticals Joaquin Duato said during an R&D briefing May 17.

The diversified healthcare giant presented a sweeping overview of its pharmaceutical portfolio and pipeline during a five-hour investor meeting near...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.